Medical Treatment of Parkinson’s Disease
Parkinson’s disease (PD) is a progressive neurodegenerative disease. It’s main feature is the nigrostriatal neuronal cell loss resulting in striatal dopamine (DA) deficiency. L-dopa + peripheral amino acid decarboxylase inhibitor (DDI: Sinemet or Madopar) is still the most effective agent for the symptomatic treatment of PD, but the dopa therapy is far from perfect. For advanced cases especially for patients with wearing off of the drug effect, fluctuation of response and “on-off, ” the conventional preparation such as Sinemet or Madopar due to their short T1/2 is no longer suitable for clinical use. Thus controlled release preparation e.g. Sinemet CR or Madopar HBS is preferable.